Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study

@inproceedings{Hitchings2021EffectivenessOC,
  title={Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study},
  author={Matthew D. Hitchings and Otavio Tavares Ranzani and Maria K S Torres and Silvano Barbosa de Oliveira and Maria Almiron and Rami Said and R. Borg and Wade L. Schulz and Roberto Dias de Oliveira and Patr{\'i}cia Vieira da Silva and Daniel Barros de Castro and Vanderson Sampaio and Bernardino Cl{\'a}udio de Albuquerque and Tatyana Costa Amorim Ramos and Shadia Hussami Hauache Fraxe and Cristiano Fernandes da Costa and Felipe Gomes Naveca and Andr{\'e} Machado Siqueira and Wildo Navegantes de Ara{\'u}jo and Jason R. Andrews and Derek A. T. Cummings and Albert I. Ko and Julio Croda},
  booktitle={medRxiv},
  year={2021}
}
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant P.1 emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread P.1 transmission has not been reported. Methods We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where P… 
Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
TLDR
CoronaVac was 42% effective in the real-world setting of extensive P.1 transmission, but significant protection was not observed until completion of the two-dose regimen, underscore the need to maintain non-pharmaceutical interventions when mass vaccination with CoronaVac is used as part of an epidemic response.
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
TLDR
It is shown that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose, and against any COVID-19 hospitalization and death, even after a single dose.
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
TLDR
The results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine.
Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil
TLDR
Observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.
Vaccine Effectiveness against Referral to Hospital and Severe Lung Injury Associated with COVID-19: A Population-based Case-control Study in St. Petersburg, Russia
TLDR
COVID-19 vaccination was effective against referral to hospital in patients with symptomatic SARS-CoV-2 infection in St. Petersburg, Russia, and a sharp increase was observed in the probability of hospital admission with age for non-vaccinated patients in relation to an almost flat relationship for the completely vaccinated group.
The Immune Response to SARS-CoV-2 and Variants of Concern
TLDR
What is known about the humoral and cellular immune responses to SARS-CoV-2 and how mutation and structural/functional changes in the emerging variants of concern impact upon the immune protection from prior infection or vaccination are reviewed.
Survival of health workers infected by SARS-CoV-2 in the context of vaccination against COVID-19 in Peru
TLDR
A positive change has been evidenced in the level of survival of health workers infected by SARS-CoV-2 during the context of vaccination against COVID-19 in Peru.
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
TLDR
None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants, and no definitive relationship could be established between vaccination administration and the occurrence of complications.
SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments
TLDR
The findings indicate that in cases of limited vaccine protection, infection is not restricted to VOCs or high-risk settings, highlighting the critical need for continued testing and monitoring of infection among individuals regardless of vaccination status.
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein
...
...

References

SHOWING 1-10 OF 41 REFERENCES
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
TLDR
Molecular clock analysis shows that P.1 emergence occurred around mid-November 2020 and was preceded by a period of faster molecular evolution, which may exhibit increased transmissibility and/or immune evasion, which is critical to accelerate pandemic responsiveness.
Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3
TLDR
The present study provides the first evidence of the new VOC P.1.1 causing multiple reinfections during the second epidemic peak in the Amazonas state and suggests that reinfected individuals may have been infectious.
Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil
TLDR
A novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein associated with increased binding to the human ACE2 receptor, is identified in Manaus, Brazil.
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
TLDR
In vitro microneutralization assays with a recombinant (r)SARS-CoV-2 virus that is identical to USA-WA1/2020 except for the E484K mutation introduced in the spike RBD suggest vaccinees are less protected against newly emerging variants.
Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area.
TLDR
In hospitalized patients, males were more likely to have complications, require ICU admission and mechanical ventilation, and have higher mortality than females, independent of age, and sex disparities in COVID-19 vulnerability are present.
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
TLDR
A positive association between higher per-capita income and COVID-19 diagnosis was identified and the severe acute respiratory infection cases with unknown aetiology were associated with lower per-Capita income.
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
TLDR
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
...
...